Target intelligence / Profile preview

DNA topoisomerase I-DNA complex (Topo I)

Target
Topo I
Molecular classification
Enzyme, DNA modifying enzyme, Type I topoisomerase
01

Overview

DNA topoisomerase I is a ubiquitous enzyme present in all domains of life that modifies DNA topology by creating transient single-strand breaks, allowing relaxation of supercoiled DNA necessary for replication, transcription, and chromosome segregation. In its catalytic cycle, topoisomerase I forms a short-lived covalent intermediate with DNA via a tyrosine residue in its active site ("DNA topoisomerase I-DNA complex") before religating the strand; therapeutic inhibition stabilizes this complex, converting a transient step into a cytotoxic lesion. Drugs exploiting this mechanism are used primarily in cancer chemotherapy and act as "topoisomerase poisons" by arresting the religation step and promoting persistent DNA damage that triggers cell death, especially in tumor cells with defective DNA damage checkpoints.

Other names
Topoisomerase ITopo IType I DNA topoisomeraseDNA topoisomerase type I
02

Mechanism of action

Topoisomerase I inhibitors bind and stabilize the Topoisomerase I-DNA covalent complex, preventing religation of the nicked DNA strand and inducing single-strand breaks, ultimately leading to replication fork collapse, double-strand breaks, apoptosis, and cell death

03

Biological functions

DNA replicationDNA transcriptionChromosome segregationDNA recombinationChromatin remodeling
04

Disease associations

CancerInfection
05

Safety considerations

Myelosuppression (especially neutropenia with irinotecan/topotecan)Gastrointestinal toxicity (diarrhea with irinotecan)Secondary malignancies due to DNA breaksResistance due to efflux pump activity and repair pathway mutations
06

Interacting drugs

Irinotecan

8 more in the full profile.

07

Biomarkers

Topoisomerase I expression levels (sometimes used to stratify sensitivity to Topoisomerase I inhibitors in cancer)DNA damage markers (e.g., γ-H2AX) indicating drug-induced breaksTumor genetic status affecting drug resistance/sensitivity (e.g., p53 status, checkpoint defects)

Beyond the preview

Go deeper on DNA topoisomerase I-DNA complex (Topo I).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on DNA topoisomerase I-DNA complex (Topo I).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call